On July 17, 2026, the U.S. Department of Defense awarded Accenture ACN Federal Services a contract aimed at evaluating and enhancing domestic pharmaceutical manufacturing capabilities. This firm-fixed-price contract, stemming from collaboration with the Defense Health Agency and the Defense Logistics Agency, focuses on diversifying manufacturing options for military use. The financial details surrounding the contract have not been disclosed, as they were redacted from the public procurement documents.
- Accenture’s current P/E ratio is 11.5x, indicating a relatively low valuation compared to its earnings.
- GF Score™: 77/100, suggesting strong potential for long-term returns.
- Insider activity shows $0.9 million in shares sold over the past three months, indicating some caution among insiders.
What’s Behind the News?
This recent contract awarded to Accenture reflects a strategic initiative by the U.S. Department of Defense to enhance its medical supply chain and ensure more resilient sources for pharmaceuticals. The emphasis on domestic manufacturing capabilities not only aims to diversify options for military use but also underscores a growing focus on national security in healthcare logistics. As global supply chains have faced disruptions, the Defense Department’s move highlights the importance of securing reliable sources for essential medical supplies.
Accenture PLC is a leading IT services firm that provides consulting, system integration, and business process outsourcing to enterprises worldwide. With a market capitalization of approximately $88 billion, Accenture operates in the technology sector, specifically within the software industry. The company serves a diverse clientele across various sectors, including communications, media and technology, financial services, health and public services, consumer products, and resources. With around 800,000 employees in over 120 countries, Accenture is the world’s largest professional services company by headcount.
How Is ACN Valued?
Currently, GF Value™ data is not available for Accenture. However, the company’s P/E ratio stands at 11.5x, which is significantly lower than the historical median P/E ratio of 26.71. This suggests that the stock may be undervalued relative to its earnings potential. Investors often look for stocks with lower P/E ratios as potential opportunities for growth. For more detailed valuation metrics, visit the ACN stock page.
What Does ACN’s GF Score™ Tell Us?
The GF Score™ ranks stocks from 0 to 100 based on five key aspects: Financial Strength, Profitability, Growth, Valuation, and Momentum. Stocks with higher GF Score™ values have been found to generate higher long-term returns (backtested 2006-2021).
| GF Score™ | 77 |
| Financial Strength | 8/10 |
| Profitability | 9/10 |
| Growth | 9/10 |
Accenture’s strengths lie in its robust financial health, with a Financial Strength rating of 8/10 and a Profitability rank of 9/10. The company’s growth metrics are also impressive, with a Growth rank of 9/10, indicating consistent revenue and earnings growth. However, the valuation aspect may require further scrutiny, especially in light of recent insider selling activity. For additional insights, visit the ACN stock page.
What Are Insiders Doing with ACN Stock?
In the past three months, insiders have sold approximately $0.9 million worth of shares, with no purchases reported during the same period. This activity may suggest a cautious outlook among insiders regarding the company’s near-term performance.
What This Means for Investors
Overall, Accenture appears to be a solid company with strong financial metrics and a favorable GF Score™ of 77. However, the recent insider selling may warrant attention from potential investors. The low P/E ratio compared to historical norms suggests that the stock could be undervalued, providing an opportunity for growth. For the complete analysis, visit the ACN stock page. You can also use the GuruFocus Stock Screener to find similar opportunities.
Frequently Asked Questions
What is ACN’s GF Score™?
ACN’s GF Score™ is 77/100, indicating strong potential for long-term returns based on its financial health, profitability, and growth metrics.
How is ACN valued?
ACN has a P/E ratio of 11.5x, which is significantly lower than its historical median P/E ratio, suggesting that the stock may be undervalued relative to its earnings potential.
What is ACN’s P/E ratio compared to historical?
ACN’s current P/E ratio of 11.5x is notably lower than its historical median P/E ratio of 26.71, indicating a potential undervaluation in the market.
This stock alert was generated using automated technology and GuruFocus financial data to provide readers with timely and accurate market reporting. This content was reviewed by GuruFocus editorial team prior to publication. Please send any questions or comments about this story to [email protected].